Vitestro begins blood-drawing device study
Technology combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion
Read Moreby John Pinching | Sep 6, 2023 | News | 0
Technology combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion
Read Moreby John Pinching | May 23, 2023 | News | 0
Vital financing will allow the company to build a pipeline of novel therapies targeting serious conditions
Read Moreby John Pinching | Apr 24, 2023 | News | 0
MDG1011 is a therapy which aims to improve outcomes for in patients with high-risk blood cancers
Read Moreby John Pinching | Mar 21, 2023 | News | 0
Company raises €12m in financing with a view to entering to the European market
Read Moreby John Pinching | Aug 11, 2022 | News | 0
University of Aberdeen team suggest results indicate that protein PAI-1 could be an early indicator of severe COVID-19
Read Moreby John Pinching | Jul 26, 2022 | News | 0
Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation
Read Moreby John Pinching | Jul 11, 2022 | News | 0
Data demonstrates that efanesoctocog alfa provides superior bleed protection
Read Moreby John Pinching | Jun 28, 2022 | News | 0
New data will be released at the International Society on Thrombosis and Haemostasis Congress
Read Moreby John Pinching | Jun 20, 2022 | News | 0
The discovery may lead to development of drugs that halt disease progression and stop memory loss
Read Moreby Anna Smith | Jul 18, 2019 | News | 0
The Mitomic Prostate Test has a 92% sensitivity, which means that men with a positive result can be referred for immediate medical intervention.
Read Moreby Anna Smith | Apr 26, 2019 | News | 0
The method would work by analysing the genetic faults in a sample of their blood.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
